ArticleCell biochemistry and function2026
Modulation of Prostate Cancer Cell Behavior Through Acetylsalicylic Acid-Treated Prostate Epithelial Cell-Derived Conditioned Medium.
Article in Cell biochemistry and function, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Acetylsalicylic acid (ASA, aspirin), derived from salicylic acid in willow bark, is known for its analgesic, anti-inflammatory, and antiplatelet properties. Beyond cardiovascular protection, increasing evidence suggests that ASA may reduce the risk of various cancers, including colorectal and prostate cancer. In this study, the effect of ASA-treated prostate epithelial cells (RWPE-1) on the proliferation and migration of prostate cancer cells was investigated. RWPE-1 cells were exposed to different ASA concentrations, and non-toxic concentrations were selected. Conditioned media (CM) from untreated and ASA-treated RWPE-1 cells were applied to PC-3 prostate cancer cells. Cell viability was assessed using the MTT assay, while migration was evaluated using the wound-healing assay, and colony formation was also assessed. ASA at 50 μM showed no cytotoxic effect on RWPE-1 cells, while CM1 (ASA 50 μM) reduced PC-3 cell viability to 60%. Moreover, CM1 (ASA 50 μM) and CM2 (ASA 25 μM) significantly inhibited PC-3 cell migration. Comparing CM groups revealed that ASA exposure alters the secretome of prostate epithelial cells, thereby reducing cancer cell viability and motility. These findings suggest that ASA may serve as a promising chemopreventive and therapeutic agent for prostate cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.